Working… Menu
Trial record 81 of 520 for:    melanoma phase III

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00087776
Recruitment Status : Completed
First Posted : July 16, 2004
Last Update Posted : January 24, 2018
Information provided by:
American Regent, Inc.

Brief Summary:
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine. In addition, the response rate to each drug, response duration, time to progression and time to treatment failure will be measured. Toxicity will be evaluated and compared between the two groups.

Condition or disease Intervention/treatment Phase
Malignant Melanoma Drug: Chemotherapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 575 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
Study Start Date : October 2002
Actual Primary Completion Date : October 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have malignant melanoma, and documented metastatic disease.
  • Patients must have at least one unidimensionally measurable lesion.
  • Patients must not have received prior systemic chemotherapy for metastatic disease. Prior treatment with immunotherapy or vaccine therapy is allowed provided there is documentation of disease progression.
  • At least 6 weeks (42 days) since any prior immunotherapy, cytokine, biologic, vaccine or other therapy unless patients have progressed during immunotherapy.
  • At least 4 weeks (28 days) since any prior radiotherapy.
  • Lesions being used to assess disease status may not have been radiated.
  • Patients must have ECOG performance status of 0 - 2.
  • Patients must be >= 18 years of age.
  • Patients must have adequate renal and liver function
  • Patients must have adequate bone marrow function.
  • Life expectancy of at least 3 months.
  • Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution.

Exclusion Criteria:

  • Patients who have received prior therapy with any taxane or dacarbazine.
  • Patients whose primary site is the eye.
  • Patients who have a past or current history of neoplasm other than the entry diagnosis, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or other cancers cured by surgery alone with a disease-free survival longer than 5 years.
  • Patients with uncontrolled brain metastasis.
  • Patients who are pregnant or nursing and patients who are not practicing an acceptable method of birth control. Patients may not breastfeed while on this study.
  • Patients with current active infections requiring anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals).
  • Patients with current peripheral neuropathy of any etiology that is greater than grade 1.
  • Patients with unstable or serious concurrent medical conditions are excluded.
  • Patients with a known hypersensitivity to Cremophor.
  • Patients must not have had recent major surgery within the past 14 days or large field radiation therapy, chemotherapy, endocrine therapy in the last 28 days, or biologic therapy in the last 42 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00087776

Layout table for location information
United States, Pennsylvania
Luitpold Pharmaceuticals, Inc.
Norristown, Pennsylvania, United States, 19403
Sponsors and Collaborators
American Regent, Inc.

Layout table for additonal information Identifier: NCT00087776     History of Changes
Other Study ID Numbers: P01-02-17
First Posted: July 16, 2004    Key Record Dates
Last Update Posted: January 24, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas